Management of benign prostate hyperplasia (BPH) by combinatorial approach using alpha-1-adrenergic antagonists and 5-alpha-reductase inhibitors

2020/06/24 by Osama A. Zitoun, Abdulrahman M. Farhat, Abdulrahman MN. Farhat +5 · 8 citations
Medicine · #5 Alpha-Reductase Inhibitor #Alpha (finance) #Benign prostatic hyperplasia (BPH) #Clinical trial #Combination therapy #Finasteride #Hormonal and reproductive studies #Hyperplasia #Internal medicine #International Prostate Symptom Score #Lower urinary tract symptoms #Medicine #Oncology #Patient satisfaction #Prostate #Prostate Cancer Diagnosis and Treatment #Randomized controlled trial #Surgery #Urinary Bladder and Prostate Research #Urology

paper · doi:10.1016/j.ejphar.2020.173301

openalex publication_date 2020/06/24 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/26

Cited by

• Benign Prostatic Hyperplasia Increases Long-term Chronic Kidney Disease Risk
• Treatment of Benign Prostatic Hyperplasia by Natural Drugs. [europepmc]
• Omentin-1 inhibits the development of benign prostatic hyperplasia by attenuating local inflammation. [europepmc]
• Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis. [europepmc]
• Protective effect of the hydroethanolic extract of camelthorn (Alhagi maurorum) on benign prostatic hyperplasia induced by testosterone in rats. [europepmc]
• Prospective observational study of oxidative stress in the pathology of benign prostatic hyperplasia with bladder diverticulum. [europepmc]
• Diagnosis and Treatment of Benign Prostatic Hyperplasia in Dogs: New Approaches. [europepmc]
• A Trifluoromethyl Quinazoline Compound Regulates the Epithelial-Mesenchymal Transition of Prostatic Hyperplasia Cells by Inhibiting the Secretion of TGF-β1 in Stromal Cells. [europepmc]